Business Context and Reporting Period
Company: Aspen Aerogels, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 29, 2022
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational performance metrics. Specific figures include:
- Shares Offered: 25,263,158 shares of common stock.
- Offering Price: $9.50 per share.
- Expected Gross Proceeds: Approximately $240 million (before underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 3,789,473 additional shares.
- Anticipated Closing Date: On or about December 2, 2022.
Note: The filing text does not provide current values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of an underwriting agreement with Cowen and Company, LLC and Barclays Capital Inc. This represents a significant increase in the company's capital base pending the closing of the transaction. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release on November 30, 2022, confirming the pricing of the offering. The proceeds are intended to be used as described in the related prospectus supplement, though specific allocation details are not in this text.
Risks and Contingencies:
- The offering is subject to customary closing conditions.
- Forward-looking statements regarding the completion of the offering and use of proceeds are subject to risks and uncertainties.
- Actual results may differ materially due to market conditions and other factors detailed in the company's Form 10-K and Form 10-Q filings.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and expenses.
- Confirm whether the underwriters exercised the over-allotment option for the additional 3,789,473 shares.
- Review the final prospectus supplement for the specific intended use of proceeds.
- Check subsequent filings for any updates on the satisfaction of closing conditions.